Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA rejects Not-Milkman petition

FDA has rejected a Citizen Petition that sought to have Monsanto's Posilac recombinant bovine growth hormone (rbGH) pulled from the market because of concerns that it may cause adverse health effects. In an April 20

Read the full 359 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE